Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.58 |
| ▸ | HTR3B | O95264 | 1/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31514814 | 1.00 | HTR3A (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL21714174 | 1.00 | HTR3A (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL2172069 | 0.98 | HTR3A (0.56) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL21492975 | 0.98 | HTR3A (0.56) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL28317303 | 0.87 | ADRB1 (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL1857426 | 0.82 | LMNA (0.49) | ALDH1A1ADAM10MMP2MMP9MMP14 | |
| SCHEMBL1366770 | 0.82 | ADAM10 (0.42) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL232730 | 0.81 | ALDH1A1 (0.55) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL31575883 | 0.81 | ALDH1A1 (0.55) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL13354909 | 0.80 | DRD2 (0.53) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | disclosed |
| WO-2018078360-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2018-05-03 | — | — | WO | disclosed |
| US-9440958-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2016-09-13 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-8980902-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8980902-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2005117882-A9 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORP (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2005117882-A9 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORP (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005117882-A2 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005117882-A2 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | SHH, GLI1, SMO | HTR3A 3181/4885HTR3E 3591/4885HTR3B 2923/4885 |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | SHH, GLI1, SMO | HTR3A 3203/4885HTR3E 3609/4885HTR3B 2854/4885 |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | CBR1, CBR3, CNR1 | HTR3A 782/4885HTR3E 1382/4885HTR3B 1248/4885 |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | HTR3A 2637/4885HTR3E 2057/4885HTR3B 2952/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | HTR3A 1989/4885HTR3E 1938/4885HTR3B 2408/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | HTR3A 1341/4885HTR3E 1485/4885HTR3B 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.